First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk

Prenatal Diagnosis - Tập 29 Số 8 - Trang 781-789 - 2009
Asma Khalil1, Nicholas J. Cowans2, Kevin Spencer3,2, Sergey Goichman4, Hamutal Meiri5, Kevin Harrington1
1Department of Obstetrics & Gynaecology, Queen Mary, University of London, UK
2Prenatal Screening Unit, Department of Clinical Biochemistry, King George Hospital, London, UK
3Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK
4TechnoStat, Ra'anan, Israel
5Diagnostic Technologies, Yokneam, Israel

Tóm tắt

AbstractObjective

To evaluate whether first trimester maternal serum PP13 can predict pre‐eclampsia among women with a priori high risk.

Method

This was a nested case–control study. Women less than 14 weeks' gestation at increased risk of developing pre‐eclampsia were recruited. Venous blood samples were assayed for PP13 using enzyme‐linked immunosorbent assay. PP13 multiples of median (MoM) were calculated and adjusted for body mass index, ethnicity, smoking, maternal age and parity. For each case of pre‐eclampsia (n = 42), five controls were randomly selected. PP13 levels were compared between women who developed pre‐eclampsia and controls using the Wilcoxon rank sum test. Sensitivity and false‐positive rates were derived from receiver operating characteristic curves.

Results

Women who developed pre‐eclampsia had significantly lower (P < 0.001) PP13 MoMs compared with controls. PP13 MoMs for controls and pre‐eclampsia cases were 1.0 (range 0.0–10.0) and 0.4 (range 0.0–7.0), respectively (P < 0.001). At a MoM cutoff of 0.53, for a false‐positive rate of 10%, sensitivity was 50% for pre‐eclampsia at term (>37 weeks), 62% for preterm pre‐eclampsia (<37 weeks) and 71% for early‐onset pre‐eclampsia (<34 weeks).

Conclusion

First trimester PP13 can predict pre‐eclampsia in women at increased a priori risk and predicts early‐onset better than late‐onset disease. Copyright © 2009 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(07)60712-0

10.1136/bmj.39335.385301.BE

10.3109/10641950109152635

10.1016/j.placenta.2003.12.009

10.1016/j.ajog.2007.02.025

10.1016/S0029-7844(01)01569-1

10.1002/pd.1921

Cuckle HS, 2000, Antenatal and Neonatal Screening, 1

Duley L, 2007, Antiplatelet agents for preventing pre‐eclampsia and its complications, Cochrane Database Syst Rev, CD004659

10.1007/978-1-4899-4541-9

10.1016/j.ajog.2006.11.002

10.1111/j.1471-0528.2008.01902.x

10.1111/j.1471-0528.1997.tb11977.x

10.1046/j.1469-0705.2000.00002.x

10.1016/S0002-9440(10)61778-6

10.1159/000151344

10.1136/bmj.323.7323.1213

10.1111/j.1471-0528.1986.tb07830.x

10.1056/NEJMoa055352

Lewis GE, 2004, Why Mothers Die. Confidential Enquiry into Maternal and Child Health. Improving the Health of Mothers, Babies and Children: The Sixth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom

Lewis GE, 2007, The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: Reviewing Maternal Deaths to Make Motherhood Safer—2003–2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom

10.1046/j.0960-7692.2001.00594.x

10.1111/j.1471-0528.1994.tb13182.x

10.1002/uog.2686

10.1080/14767050701500349

10.1126/science.1111726

10.1016/S0140-6736(00)03577-7

Robertson WB, 1985, Abnormal placentation, Obstet Gynecol Annu, 14, 411

10.1016/j.ajog.2008.01.013

10.1080/14767050701830480

10.1016/S0140-6736(05)17987-2

10.1016/S0146-0005(03)00022-3

10.1002/pd.1664

10.1002/uog.3876

10.1002/pd.1890

10.1002/pd.1251

10.1210/jc.2003-031244

10.1007/s00428-008-0658-x

10.1111/j.1432-1033.2004.04004.x

10.1053/plac.1999.0436

10.1081/PRG-120021060

10.1016/S0140-6736(00)02800-2

Thông tin
Thông tin xuất bản

Prenatal Diagnosis

Tập 29 Số 8

781-789

Thông tin tác giả